Jiajia Bao

ORCID: 0000-0002-9274-0393
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • MicroRNA in disease regulation
  • Viral Infections and Immunology Research
  • RNA regulation and disease
  • Tuberculosis Research and Epidemiology
  • Mycobacterium research and diagnosis
  • RNA modifications and cancer
  • Immune Cell Function and Interaction
  • Ferroptosis and cancer prognosis
  • Circular RNAs in diseases
  • Chemical Reactions and Isotopes
  • Immune Response and Inflammation
  • Cancer therapeutics and mechanisms
  • Cancer-related molecular mechanisms research
  • RNA Research and Splicing
  • interferon and immune responses

Chongqing Medical University
2021-2025

Tuberculosis remains a major global health threat, with traditional antibiotic treatments facing challenges such as drug resistance. Host-directed therapy (HDT) has emerged promising approach to combat tuberculosis by enhancing the host immune response. CXCL14, chemokine family member, plays crucial role in regulating antipathogenic responses. To elucidate of CXCL14 and its key regulatory molecules mycobacterial infections, we identified new targets for host-directed therapy. RAW264.7...

10.1021/acsinfecdis.4c00856 article EN ACS Infectious Diseases 2025-03-18

Mycobacterium tuberculosis (M. tuberculosis) is the causative agent of tuberculosis. As an important component host immunity, macrophages are not only first line defense against M. but also parasitic site in host. Glucocorticoids can cause immunosuppression, which considered to be one major risk factors for active tuberculosis, mechanism unclear.To study effect methylprednisolone on proliferation mycobacteria and try find key molecules this phenomenon.The macrophage RAW264.7 infected by...

10.3390/microorganisms11030768 article EN cc-by Microorganisms 2023-03-16

Drug resistance is a prominent problem in the treatment of tuberculosis, so it urgent to develop new anti- tuberculosis drugs. Here, we investigated effects and mechanisms cisplatin (DDP) on intracellular Mycobacterium smegmatis tap therapeutic potential DDP mycobacterial infection.Macrophages infected with were treated alone or combined isoniazid rifampicin. The results showed that bacterial count macrophages decreased significantly after (≤ 6 μg/mL) treatment. When rifampicin was DDP,...

10.1371/journal.pone.0281170 article EN cc-by PLoS ONE 2023-01-31

Among the PLWH (people living with HIV) population, risk of developing active tuberculosis (TB) is increasing. Active TB also accelerates deterioration PLWH's immune function and one leading causes death in population. So far, accurate diagnosis population remains challenging. Through data analysis HIV/TB co-infection GEO database, differentially expressed genes as well their related microRNA (miRNA) were acquired further verified through clinical blood samples. Dual-luciferase assay was...

10.1021/acsinfecdis.3c00211 article EN ACS Infectious Diseases 2023-08-25

Abstract Background With the advancement of sequencing technologies, a plethora noncoding RNA (ncRNA) species have been widely discovered, including microRNAs (miRNAs), circular RNAs (circRNAs), and long ncRNAs (lncRNAs). However, mechanism these non-coding in diseases caused by enterovirus d68 (EV-D68) remains unclear. The goal this research was to identify significantly altered circRNAs, lncRNAs, miRNAs, mRNAs pathways RD cells infected with EV-D68, analyze their target relationships,...

10.1186/s12985-021-01686-x article EN cc-by Virology Journal 2021-11-07

To explore the serum levels of IL-39, CXCL14, and IL-19 in patients with tuberculosis (TB) along their clinical significances concentration changes macrophages after Bacille Calmette-Guérin vaccine (BCG) or Mycobacterium (M. tb) H37Rv stimulation vitro. The 38 TB patients, 20 healthy staff members were measured by enzyme-linked immunosorbent assay. Moreover, IL-19, IL-39 cultured THP-1 detected at 12, 24, 48 h BCG M. tb strains. It was found level significantly reduced CXCL14 remarkably...

10.1515/biol-2022-0594 article EN cc-by-nc-nd Open Life Sciences 2023-01-01
Coming Soon ...